Join the club for FREE to access the whole archive and other member benefits.

New missile-like radioactive therapy treats prostate cancer


Key points from article :

New high-tech drug treatment for prostate cancer can keep patients alive and healthy for longer, a new phase III trial reports.

The search and destroy treatment could shrink tumours while leaving healthy cells unharmed.

Uses a homing device to seek out cancers by detecting the prostate-specific membrane antigen (PSMA) on the surface of cancer cells.

Clinical trial involved 831 participants with PSMA-positive advanced prostate cancer.

Adding 177Lu-PSMA-617 to standard care extended patients’ lives by 4 months.

Men were 38% less likely to die during the 20.9-month follow-up.

“This new treatment acts like a guided missile seeking out cancer cells," - Johann de Bono, study co-author.

“A smarter, kinder treatment...while reducing the risk of side effects," - Paul Workman, Chief Executive of ICR.

Research by ICR, Royal Marsden NHS Foundation Trust, and Memorial Sloan Kettering Cancer Center, to be presented at the ASCO.

Precisely targeted therapy shrank tumours and extends life by 38% in men

Mentioned in this article:

Tap on icon for description, click on resource name for more details.


Non-profit organization for advancing cancer research


Consultant at the Institute of Cancer Research

Health Organisation

Cancer treatment and research institution in New York City


Chief Executive and President of The Institute of Cancer Research.


Hospital dedicated to cancer diagnosis, treatment, research and education.